Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants

Megan Griffiths, Jun Yang, Allen D. Everett, Jacky M. Jennings, Grace Freire, Monica Williams, Melanie Nies, Sharon A. McGrath-Morrow, Joseph M. Collaco

Research output: Contribution to journalArticlepeer-review


Introduction: Pulmonary hypertension (PH) is a common comorbidity of cardiopulmonary disease. Endostatin, an inhibitor of angiogenesis, is elevated in neonates with lung disease. ST2 is a heart failure biomarker correlated with PH in adults. We hypothesized that these biomarkers may be useful in diagnosing PH and categorizing its severity in infants. Methods: Endostatin, ST2, and NT-proBNP plasma concentrations from 26 infants with PH and 21 control infants without PH were correlated with echocardiographic and clinical features using regression models over time. Results: Endostatin, ST2, and NT-proBNP concentrations were elevated in PH participants versus controls (p < 0.0001). Endostatin was associated with right ventricular dysfunction (p = 0.014), septal flattening (p = 0.047), and pericardial effusion (p < 0.0001). ST2 concentrations predicted right to left patent ductus arteriosus flow (p = 0.009). NT-proBNP was not associated with PH features. Conclusions: Endostatin and ST2 concentrations were associated with echocardiographic markers of worse PH in infants and may be better predictors than existing clinical standards.

Original languageEnglish (US)
Pages (from-to)1625-1633
Number of pages9
JournalJournal of Perinatology
Issue number11
StatePublished - Nov 1 2020

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants'. Together they form a unique fingerprint.

Cite this